Targeting endothelin receptors: A promising strategy for alleviating
cancer-related and non-cancer pain in Animal Models
Muhammad Mohsin1*, Yusra Afzal2, Bo-Ya Hu1,
Zuo-Jie Jiang1, Peng-Bo Jing1, Hao-Hao Chen1,
Muhammad Tahir Aleem1, Ashiq Ali1, Shahbaz Ul
Haq1, Shakeel Ahmed3,1, Mohsan Ullah Goraya4,
Bilal Murtaza5, Asghar Abbas6, Kashif Hussain6,
Fen-Fei Gao1* and Xing-Jun Liu1,7*
1Shantou
University Medical College, Shantou, Guangdong Province 515041,
China; 2Government College Women University Faisalabad,
Pakistan;3Shaheed Benazir Bhutto University of Veterinary
and Animal Sciences Sakrand, Sind, Pakistan; 4School of
Medicine, Huaqiao University Quanzhou, Quanzhou, China; 5School
of Bioengineering, Dalian University of Technology, Dalian, China;
6Department of Veterinary and Animal Sciences, Muhammad
Nawaz Sharif University of Agriculture Multan, Pakistan; 7School
of Pharmacy, Nantong University, Nantong, Jiangsu Province 226001,
China
*Corresponding author:
onlymohsindvm@gmail.com;
ffgao@sru.edu.cn;
edvin201@163.com
Abstract
Endothelin is a potent vasoconstrictor known to play a role in various painful
conditions. This study aims to explore the role of the endothelin system,
including its receptors, isoforms, and converting enzymes, in the pathogenesis
of cancerous and non-cancerous ailments. Additionally, it evaluates the efficacy
of endothelin receptor antagonists in managing pain associated with these
conditions. A review of recent studies was conducted to identify the fundamental
activities of the endothelin system and the impact of antagonists targeting
endothelin receptors on pain relief. The endothelin system has emerged as a
crucial player in various painful conditions. Antagonists targeting endothelin
receptors have shown promise in alleviating cancer pain, with endothelin
secretion observed in cancer cells of diverse histologic types. Moreover,
endothelin receptor antagonists have demonstrated potential in managing
neuropathic and inflammatory pain syndromes. Therapies targeting the endothelin
system, particularly endothelin receptor antagonists, hold significant promise
for managing both cancer-related and non-cancer-related pain syndromes,
highlighting the therapeutic potential of these agents in pain management.
To Cite This Article:
Mohsin M, Afzal Y, Hu BY, Jiang ZJ, Jing PB, Chen HH, Aleem MT, Ali A, Haq S,
Ahmed S, Goraya M, Murtaza B, Abbas A, Hussain K, Gao FF and Liu XJ,
xxxx.
Targeting endothelin receptors: A promising strategy for alleviating
cancer-related and non-cancer pain in animal models.
Pak Vet J. http://dx.doi.org/10.29261/pakvetj/2024.208